Following the clinical and commercial success of monoclonal antibodies, Fc-based therapies have captured substantial attention in the biopharmaceutical industry; however, their inherent complexity continues to present manufacturability challenges in both upstream and downstream processes. We describe high titer expression of Fc-fusion proteins using FUJIFILM Diosynth Biotechnologies’ Apollo™ X platform coupled with integrated quality assessments, enhancing our support for clients through the predicted growth in Fc-fusion clinical applications.

pen and paper stack

Download whitepaper

By Leon Pybus, Fay Saunders, Devika Kalsi, Jeffrey Keen, Jessica Kane-Fidgeon, Daniel Sharkey, Yuta Murakami, Tatsuya Matsuura, Kenta Seko